Our Pricing

Wegovy Weight Loss: Your Complete Starter Guide From £69.00

Published on: June 03, 2026

This wegovy weight loss starter guide uk provides everything you need to know before starting semaglutide injections for weight management. Wegovy (semaglutide 2.4mg) is a once-weekly injectable treatment licensed by the MHRA for adults with a BMI of 30 or above, or 27 with weight-related health conditions. At Cured Pharmacy, Wegovy starts from £79.00 with a free online consultation completed in under three minutes by our UK-registered clinical team.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your body produces after eating [1]. This medication works through three primary mechanisms: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and helps regulate blood sugar levels. Unlike older weight loss medications that work peripherally, semaglutide acts on central appetite pathways in the hypothalamus.

In the landmark STEP 1 clinical trial involving 1,961 adults, participants using Wegovy 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 86.4% of Wegovy users lost at least 5% of their starting weight, and more than half achieved weight loss exceeding 15% [1]. These results represent some of the most significant weight reductions observed in pharmaceutical trials for obesity management.

Semaglutide's efficacy extends beyond the number on the scales. The STEP trials demonstrated improvements in cardiometabolic markers including waist circumference, blood pressure, HbA1c levels, and lipid profiles [2]. For patients with type 2 diabetes, the SELECT cardiovascular outcomes trial showed semaglutide reduced major adverse cardiovascular events by 20% compared to placebo [3].

Wegovy Dosing Schedule: The Gradual Titration Approach

Wegovy follows a carefully designed dose escalation protocol over 16-20 weeks to minimise gastrointestinal side effects whilst your body adjusts to the medication. This gradual titration is clinically important — starting at the full 2.4mg maintenance dose would significantly increase the risk of nausea, vomiting, and treatment discontinuation.

The standard UK dosing schedule begins with 0.25mg once weekly for four weeks, then increases to 0.5mg for four weeks, followed by 1.0mg for four weeks, then 1.7mg for four weeks, before reaching the maintenance dose of 2.4mg weekly. Each pre-filled pen contains a single dose, and you inject subcutaneously into your abdomen, thigh, or upper arm on the same day each week. If you experience persistent gastrointestinal symptoms at any stage, your prescriber may recommend staying at your current dose for an additional four weeks before escalating.

Missing a dose requires specific guidance: if fewer than five days have passed since your scheduled injection day, take the missed dose as soon as you remember. If more than five days have elapsed, skip that dose entirely and resume your regular schedule with the next injection. Never double up doses to compensate for a missed injection, as this increases the risk of adverse effects.

What to Expect During Dose Escalation

Most patients notice appetite suppression within the first two weeks, even at the 0.25mg starting dose. Weight loss typically becomes evident from week 4-8, with the rate of loss accelerating as you reach higher doses. Clinical data shows the majority of weight reduction occurs between weeks 20-60, with weight stabilising thereafter [1]. During titration, mild nausea affects approximately 44% of users but usually resolves within 4-6 weeks as your body adapts [2]. Staying well-hydrated, eating smaller portions, and avoiding high-fat meals can significantly reduce these initial side effects.

Wegovy Weight Loss Results: What Clinical Trials Show

The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness across diverse patient populations. STEP 1, the largest trial, demonstrated that after 68 weeks, participants on Wegovy lost an average of 15.3kg compared to 2.6kg in the placebo group — a difference of 12.7kg [1]. Significantly, weight loss was sustained throughout the trial period, with no plateau effect observed even after 68 weeks of treatment.

STEP 2 specifically examined semaglutide in patients with type 2 diabetes, a population that typically experiences more modest weight loss with pharmacotherapy. Even in this cohort, Wegovy 2.4mg produced an average weight reduction of 9.6% versus 3.4% with placebo over 68 weeks [4]. This demonstrates semaglutide's efficacy extends to patients with metabolic comorbidities who often struggle with conventional weight management approaches.

Real-world data from UK prescribing patterns mirrors these trial outcomes. In clinical practice, we observe that patients who adhere to the full dosing schedule and combine Wegovy with modest dietary modifications typically lose 12-18% of their starting weight within 12 months. However, individual results vary considerably based on baseline BMI, adherence, lifestyle factors, and metabolic health. Wegovy is not a standalone solution — it works most effectively as part of a comprehensive weight management programme that includes nutritional guidance and increased physical activity where appropriate.

Maintaining Weight Loss Long-Term

The STEP 4 withdrawal trial provides important insights into long-term weight maintenance. Participants who discontinued Wegovy after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks, whilst those who continued treatment maintained their weight loss [5]. This data underscores that Wegovy is a chronic treatment for a chronic condition — obesity has biological underpinnings that persist even after weight loss, and ongoing pharmacotherapy helps counteract the metabolic adaptations that drive weight regain. Your UK prescriber will discuss treatment duration during your consultation, but most patients require ongoing therapy to sustain their results.

Common Side Effects and How to Manage Them

Gastrointestinal symptoms are the most frequently reported side effects with Wegovy, affecting approximately 74% of users to some degree [2]. Nausea is most common (44%), followed by diarrhoea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). These effects are typically mild to moderate, occur predominantly during dose escalation, and resolve within 4-8 weeks as your body adapts to the medication. The gradual titration schedule is specifically designed to minimise these symptoms.

Practical strategies can significantly reduce gastrointestinal discomfort during your first months on Wegovy. Eat smaller, more frequent meals rather than three large portions. Avoid high-fat, greasy, or heavily spiced foods, which slow gastric emptying further and exacerbate nausea. Stay well-hydrated throughout the day, sipping water regularly rather than drinking large amounts at once. If nausea occurs, ginger tea, cold foods, and bland carbohydrates like crackers or toast often help. Some patients find injecting in the evening before bed means they sleep through the peak nausea period, which typically occurs 24-48 hours post-injection.

Serious adverse effects are rare but require immediate medical attention. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [6]. Do not use Wegovy if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Acute pancreatitis occurs in approximately 0.2% of users — seek urgent medical care if you develop severe, persistent abdominal pain radiating to your back [2]. Gallbladder problems, including cholelithiasis and cholecystitis, occur more frequently with rapid weight loss; report right upper quadrant pain, jaundice, or fever to your GP immediately.

Injection Site Reactions and Technique

Injection site reactions affect approximately 6% of Wegovy users and typically present as mild redness, itching, or small lumps at the injection site [2]. These usually resolve within 2-3 days. To minimise reactions, rotate your injection sites weekly between your abdomen, thighs, and upper arms — never inject into the same spot two weeks consecutively. Allow the pen to reach room temperature for 30 minutes before injecting, as cold medication increases discomfort. Inject slowly over 5-10 seconds and hold the pen in place for an additional 6 seconds after the dose counter reaches zero to ensure full delivery. If persistent injection site reactions occur, your prescriber may recommend antihistamines or alternative injection locations.

Who Can Use Wegovy: Eligibility and Contraindications

Wegovy is licensed in the UK for adults aged 18 and over with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [6]. NICE guidelines align with these criteria, recommending GLP-1 receptor agonists for weight management when lifestyle interventions alone have proven insufficient. Your UK prescriber will calculate your BMI and assess your medical history during the online consultation to determine eligibility.

Several absolute contraindications preclude Wegovy use. These include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, previous serious hypersensitivity reaction to semaglutide or any excipients, and pregnancy or breastfeeding. Wegovy should be discontinued at least two months before a planned pregnancy due to the long washout period required. Relative contraindications requiring careful assessment include diabetic retinopathy (particularly proliferative or macular oedema), severe gastrointestinal disease, history of pancreatitis, and severe renal impairment.

Drug interactions are generally minimal with Wegovy, but the delayed gastric emptying can affect absorption of oral medications, particularly those with narrow therapeutic windows. If you take levothyroxine, oral contraceptives, or medications requiring precise timing, your prescriber may recommend taking them at least one hour before your Wegovy injection. Patients using insulin or insulin secretagogues (such as sulphonylureas) require dose adjustments to prevent hypoglycaemia, as semaglutide enhances insulin secretion and improves glycaemic control. Our clinical team at Cured Pharmacy reviews all your current medications during the consultation to identify potential interactions and ensure safe prescribing.

Starting Wegovy at Cured Pharmacy: The Assessment Process

Beginning your wegovy weight loss starter guide uk journey at Cured Pharmacy involves a straightforward online consultation that takes under three minutes to complete. Our MHRA-approved assessment captures your medical history, current medications, weight management goals, and screens for contraindications. You'll provide your height, weight, and details of any previous weight loss attempts. This information is reviewed by a UK-registered prescriber — either a GP or an independent prescribing pharmacist — who determines whether Wegovy is clinically appropriate for you.

If approved, your prescription is issued electronically and dispensed by our GPhC-registered pharmacy team under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073). We supply genuine UK-licensed Wegovy pens sourced directly from licensed wholesalers — never grey market or imported products. Your first month's supply (typically four 0.25mg pens) is dispatched in 100% discreet packaging via tracked courier, with most orders arriving within 2-3 working days. Each pen comes with full patient information leaflets and injection instructions in English.

Ongoing prescriptions require brief follow-up consultations every 8-12 weeks to monitor your progress, assess tolerability, and adjust dosing if needed. Our clinical team tracks your weight loss trajectory and provides guidance on managing side effects or optimising results. You'll receive email reminders when your next assessment is due, ensuring continuity of treatment without gaps. Pricing remains transparent throughout — you'll see the exact cost before completing each consultation, with no hidden fees or surprise charges. At Cured Pharmacy, we guarantee the lowest Wegovy prices in the UK at £79.00, significantly below typical market rates whilst maintaining full clinical governance and regulatory compliance.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
3. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. MHRA. https://products.mhra.gov.uk/ [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence, lifestyle factors, and metabolic health. Wegovy is a prescription-only medication licensed for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.